The latest price target for ARS Pharmaceuticals (NASDAQ:SPRY) was reported by Roth Capital on September 4, 2025. The analyst firm set a price target for $40.00 expecting SPRY to rise to within 12 months (a possible 424.93% upside). 1 analyst firms have reported ratings in the last year.

The latest analyst rating for ARS Pharmaceuticals (NASDAQ:SPRY) was provided by Roth Capital, and ARS Pharmaceuticals initiated their buy rating.

The last upgrade for ARS Pharmaceuticals Inc happened on August 13, 2024 when Raymond James raised their price target to $22. Raymond James previously had an outperform for ARS Pharmaceuticals Inc.

The last downgrade for ARS Pharmaceuticals Inc happened on September 20, 2023 when William Blair changed their price target from N/A to N/A for ARS Pharmaceuticals Inc.

Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of ARS Pharmaceuticals, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for ARS Pharmaceuticals was filed on September 4, 2025 so you should expect the next rating to be made available sometime around September 4, 2026.

While ratings are subjective and will change, the latest ARS Pharmaceuticals (SPRY) rating was a initiated with a price target of $0.00 to $40.00. The current price ARS Pharmaceuticals (SPRY) is trading at is $7.62, which is within the analyst’s predicted range.